(Q37492596)

20 August 2017

1 reference

title

Gout--what are the treatment options? (English)

1 reference

20 August 2017

3

1 reference

20 August 2017

2

Nicola Dalbeth

1 reference

20 August 2017

Naomi Schlesinger

1

1 reference

ORCID Public Data File 2021

language of work or name

English

0 references

publication date

1 June 2009

1 reference

Expert Opinion on Pharmacotherapy

20 August 2017

published in

1 reference

20 August 2017

volume

10

1 reference

20 August 2017

issue

8

1 reference

20 August 2017

page(s)

1319-1328

1 reference

Management of acute and chronic gouty arthritis: present state-of-the-art

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Crystal-induced neutrophil activation. IV. Specific inhibition of tyrosine phosphorylation by colchicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Mechanism of Action of Colchicine in Acute Urate Crystal-Induced Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Gout-associated uric acid crystals activate the NALP3 inflammasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Does colchicine work? The results of the first controlled study in acute gout.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Hypersensitivity to Colchicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

21 January 2018

Colchicine in acute gout

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

21 January 2018

The management of gout

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Comparison of indomethacin and phenylbutazone in acute gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Double-blind study of fenoprofen versus phenylbutazone in acute gouty arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Effectiveness of etodolac (‘Lodine’) compared with naproxen in patients with acute gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Systemic steroid therapy for acute gout: a clinical trial and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Febuxostat compared with allopurinol in patients with hyperuricemia and gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Colchicine myopathy in renal transplant recipients on cyclosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Cytoskeletal myotoxicity from simvastatin and colchicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Acute gout during hypouricaemic therapy: prophylaxis with colchicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Gout epidemiology: results from the UK General Practice Research Database, 1990-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Dietary risk factors for rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: another insight to allopurinol-related toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Relation between adverse events associated with allopurinol and renal function in patients with gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Long-term efficacy of hyperuricaemia treatment in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

PEG-uricase in the management of treatment-resistant gout and hyperuricemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

The effects of vitamin C supplementation on serum concentrations of uric acid: results of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Variation in the serum creatinine assay calibration: a practical application to glomerular filtration rate estimation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

Febuxostat, a novel drug for the treatment of hyperuricemia of gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902950742

10.1517/14656560902950742

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference